Biochemical alterations associated with ALS
暂无分享,去创建一个
M. Cudkowicz | Jacob E. Wulff | M. Milburn | R. Bowser | J. Berry | J. Ryals | Kay A. Lawton | Matthew N. Jaffa | R. Lawson | Danny C. Alexander | R. Caffrey | Meredith V. Brown
[1] P. Andersen,et al. Disease-Related Changes in the Cerebrospinal Fluid Metabolome in Amyotrophic Lateral Sclerosis Detected by GC/TOFMS , 2011, PloS one.
[2] K. Kinzler,et al. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome , 2011, Proceedings of the National Academy of Sciences.
[3] A. Ludolph,et al. Energy metabolism in amyotrophic lateral sclerosis , 2011, The Lancet Neurology.
[4] D. Greenblatt,et al. A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis , 2010, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
[5] J. Yates,et al. ALS-linked mutant superoxide dismutase 1 (SOD1) alters mitochondrial protein composition and decreases protein import , 2010, Proceedings of the National Academy of Sciences.
[6] Patrick Emond,et al. 1H-NMR-Based Metabolomic Profiling of CSF in Early Amyotrophic Lateral Sclerosis , 2010, PloS one.
[7] Lining Guo,et al. Metabolomic Profiling Reveals Biochemical Pathways and Biomarkers Associated with Pathogenesis in Cystic Fibrosis Cells , 2010, The Journal of Biological Chemistry.
[8] Corey D. DeHaven,et al. Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. , 2009, Analytical chemistry.
[9] L. Schaeffer,et al. Muscle Mitochondrial Uncoupling Dismantles Neuromuscular Junction and Triggers Distal Degeneration of Motor Neurons , 2009, PloS one.
[10] E. Hogan,et al. Ceramide and neurodegeneration: Susceptibility of neurons and oligodendrocytes to cell damage and death , 2009, Journal of the Neurological Sciences.
[11] John T. Wei,et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression , 2009, Nature.
[12] J. Desport,et al. High metabolic level in patients with familial amyotrophic lateral sclerosis , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
[13] L. Mascitelli,et al. DYSLIPIDEMIA IS A PROTECTIVE FACTOR IN AMYOTROPHIC LATERAL SCLEROSIS , 2008, Neurology.
[14] M. Milburn,et al. Analysis of the adult human plasma metabolome. , 2008, Pharmacogenomics.
[15] B. Bodo,et al. Role of hypaphorine in the toxicity of Astragalus lusitanicus , 2008, Natural product research.
[16] M. Beal,et al. Mitochondrial dysfunction and amyotrophic lateral sclerosis , 2006, Muscle & nerve.
[17] V. Legué,et al. Actin organization during eucalyptus root hair development and its response to fungal hypaphorine. , 2006, Plant biology.
[18] E. Sato,et al. l-Carnitine suppresses the onset of neuromuscular degeneration and increases the life span of mice with familial amyotrophic lateral sclerosis , 2006, Brain Research.
[19] T. Conrad,et al. A clinical trial of creatine in ALS , 2004, Neurology.
[20] J. Loeffler,et al. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[21] H. Koepsell,et al. The SLC22 drug transporter family , 2004, Pflügers Archiv.
[22] John D. Storey,et al. Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[23] J. Veldink,et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis , 2003, Annals of neurology.
[24] P. Guarneri,et al. Mitochondrial oxidative metabolism in motor neuron degeneration (mnd) mouse central nervous system , 2002, The European journal of neuroscience.
[25] M. Mattson,et al. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress–induced death of motor neurons in amyotrophic lateral sclerosis , 2002, Annals of neurology.
[26] A W Partin,et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. , 2002, Urology.
[27] B. Beaufrère,et al. Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. , 2001, The American journal of clinical nutrition.
[28] O. Hardiman,et al. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study. , 2000, Archives of neurology.
[29] M. Wyss,et al. Creatine and creatinine metabolism. , 2000, Physiological reviews.
[30] E. Wouters,et al. Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones. , 1999, Clinical science.
[31] B. Poeggeler,et al. Potent Neuroprotective Properties against the Alzheimer β-Amyloid by an Endogenous Melatonin-related Indole Structure, Indole-3-propionic Acid* , 1999, The Journal of Biological Chemistry.
[32] Ole A. Andreassen,et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis , 1999, Nature Medicine.
[33] Michael Swash,et al. Early diagnosis of ALS/MND , 1998, Journal of the Neurological Sciences.
[34] V. Meininger,et al. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. , 1994, The New England journal of medicine.
[35] J. Haines,et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis , 1993, Nature.
[36] A. Steck,et al. Diagnosis of amyotrophic lateral sclerosis , 1991, Annals of neurology.